Advancing Care Across Retinal Vascular Diseases with Next-Generation Anti-VEGF Therapies
Welcome back to another Ophthalmology Times series. In this episode titled, “Advancing Care Across Retinal Vascular Diseases,” the expert faculty discussed the evolving management of retinal vascular diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The panel reviewed the significant prevalence and treatment burden associated with these chronic retinal conditions, emphasizing how frequently these diseases are encountered in clinical retina practice and the challenges associated with maintaining long-term patient adherence to therapy.
In this episode, “Diagnostic Imaging in Retinal Vascular Disease Management,” the panelists explore how recent innovations in multimodal imaging are transforming the diagnosis and management of retinal vascular diseases, including AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The expert faculty discuss the growing role of optical coherence tomography (OCT) as the foundational imaging modality in retina clinics and how additional technologies such as fundus autofluorescence, OCT angiography (OCTA), and ultra-widefield imaging are expanding clinicians’ ability to detect and monitor disease activity.
Experts discuss balancing vision, dry retina goals, fluid tolerance, and longer-lasting anti-VEGF options to cut injection burden.
Experts weigh vision-first goals in retinal disease, debating dry OCT vs stable fluid, longer anti‑VEGF intervals, and next‑gen durable therapies.
Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.
New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.
High-dose aflibercept 8 mg shows faster fluid drying and longer dosing intervals in AMD, DME and RVO, cutting injections without vision loss.
New aflibercept 8 mg label expands dosing from every 4 to 20 weeks, boosting flexibility, insurance support, and outcomes in tough retinal cases.
Clinical and real-world faricimab data reshape DME treatment strategies, highlighting durability, drying benefits, and when switching therapies may improve outcomes.
How faricimab reshapes DME care: trial vs real-world durability, Ang2/VEGF clues, when to switch, and how AI-guided OCT may help.
See how retina experts set anti-VEGF intervals: loading doses, OCT-based treat-and-extend, and why 4-month claims don’t fit all.
Ranibizumab port system delivers anti‑VEGF durability, but surgical risks, access hurdles and patient selection limit wider use.
Exploring ranibizumab port delivery: long-lasting anti-VEGF control, but surgery, access hurdles and safety tradeoffs make patient selection crucial.
Clinicians unpack anti‑VEGF access barriers—missed visits, step therapy, costs—and how bevacizumab and assistance programs keep patients treated.
Learn how missed follow-ups and insurance hurdles limit retinal anti-VEGF care—and the strategies clinicians use to keep patients treated.
